Nevro to Report Third Quarter 2020 Financial Results

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, will announce its Q3 financial results on November 5, 2020, after market close. The results will be discussed in a conference call at 1:30 PM PT/4:30 PM ET, accessible via dial-in or webcast. Nevro's Senza spinal cord stimulation system offers innovative non-drug therapies, significantly reducing or eliminating opioid use in over 65% of patients. This event is critical for investors monitoring Nevro's financial performance and future outlook.

Positive

• Innovative products improving chronic pain management.
• Senza system shown to reduce or eliminate opioids in ≥65% of patients.

Negative

• None.

REDWOOD CITY, Calif., Oct. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 after the market closes on November 5, 2020.

Management will host a conference call on November 5, 2020 to discuss third quarter 2020 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally, using Conference ID: 6693376. In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investor Relations:
Matt Bacso, CFA
ir@nevro.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-report-third-quarter-2020-financial-results-301158375.html

SOURCE Nevro Corp.

FAQ

When will Nevro release its Q3 2020 financial results?

Nevro will release its Q3 2020 financial results on November 5, 2020, after market close.

What time is the Nevro conference call for Q3 results?

The conference call will start at 1:30 PM PT/4:30 PM ET on November 5, 2020.

How can I listen to Nevro's Q3 earnings call?

You can listen to Nevro's Q3 earnings call by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally using Conference ID: 6693376.

What is the significance of Nevro's Senza system?

The Senza system offers non-pharmacologic neuromodulation, successfully reducing opioid use in a significant percentage of patients.

Where can I find Nevro's financial results?

Nevro's financial results will be available in the 'Investors' section of their website following the announcement.